NASDAQ:CDMO - US05368M1062 - Common Stock
We assign a fundamental rating of 2 out of 10 to CDMO. CDMO was compared to 542 industry peers in the Biotechnology industry. Both the profitability and financial health of CDMO have multiple concerns. CDMO is quite expensive at the moment. It does show a decent growth rate.
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -47% | ||
ROE | -339.34% | ||
ROIC | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
OM | N/A | ||
PM (TTM) | N/A | ||
GM | 7.68% |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 3.58 | ||
Debt/FCF | N/A | ||
Altman-Z | -0.51 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Current Ratio | 1.3 | ||
Quick Ratio | 0.92 |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
P/FCF | N/A | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
NASDAQ:CDMO (2/4/2025, 8:00:02 PM)
12.49
+0.01 (+0.08%)
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A | ||
P/S | 5.32 | ||
P/FCF | N/A | ||
P/OCF | 152.36 | ||
P/B | 17.88 | ||
P/tB | 17.88 | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -47% | ||
ROE | -339.34% | ||
ROCE | N/A | ||
ROIC | N/A | ||
ROICexc | N/A | ||
ROICexgc | N/A | ||
OM | N/A | ||
PM (TTM) | N/A | ||
GM | 7.68% | ||
FCFM | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 3.58 | ||
Debt/FCF | N/A | ||
Debt/EBITDA | N/A | ||
Cap/Depr | 119.78% | ||
Cap/Sales | 9.93% | ||
Interest Coverage | N/A | ||
Cash Conversion | N/A | ||
Profit Quality | N/A | ||
Current Ratio | 1.3 | ||
Quick Ratio | 0.92 | ||
Altman-Z | -0.51 |